COMMUNIQUÉS West-GlobeNewswire
-
Quotient Therapeutics Appoints Seasoned Life Sciences Executive, Susan Keefe, as Chief Financial Officer
02/02/2026 -
Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2025 Financial Results and Host Webcast on February 19, 2026
02/02/2026 -
60 Degrees Pharmaceuticals Expands Access to ARAKODA® with GoodRx Partnership
02/02/2026 -
Opus Genetics to Participate in Upcoming Medical and Industry Conferences in February 2026
02/02/2026 -
vTv Therapeutics Amends License Agreement with Newsoara Biopharma Co. Ltd. for PDE4 inhibitor, HPP737
02/02/2026 -
Aquestive Therapeutics Announces FDA Issuance of Complete Response Letter for Anaphylm™
02/02/2026 -
Nova Leap Health Corp. Launches Palliative Care Division In Nova Scotia Through Earth Angels Home Care
02/02/2026 -
Harrow Reaffirms 2025 Full-Year Revenue Guidance of $270–$280 Million, Marking Another Year of Strong Growth
02/02/2026 -
Iridex Announces Plans to Relocate Headquarters
02/02/2026 -
Wave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency
02/02/2026 -
Zevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday, February 9, 2026
02/02/2026 -
Palvella Therapeutics Announces Scientific Publication in Clinical and Experimental Dermatology Highlighting a Systematic Review of Real-World Statin Evidence and Persistent Treatment Gaps Resulting from the Lack of FDA-Approved Therapies in Porokeratosis
02/02/2026 -
Hydreight Technologies Issues Fiscal 2026 Revenue Guidance of ≈ $150 Million and Provides Q1 2026 Outlook
02/02/2026 -
EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing ≥15 kg to <30 kg
02/02/2026 -
MIMEDX Celebrates 15 Year Anniversary of EPIFIX® and AMNIOFIX®
02/02/2026 -
Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE® (roflumilast) Cream 0.05% in Infants with Mild to Moderate Atopic Dermatitis
02/02/2026 -
DLH to Announce Fiscal 2026 First Quarter Financial Results
02/02/2026 -
Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle™ Programs at the 2026 WORLDSymposium™
02/02/2026 -
Targeted Genomics Launches Celiac Genetic Testing Services for Texas Physicians
02/02/2026
Pages